Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 88-94

  Guan, Ming ^a   Xu, Chong ^b   Zhang, Fanglin ^c   Ye, Chuanzhong ^d  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

EphA7; Promoter methylation; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EPHRIN; EPHRIN A7; UNCLASSIFIED DRUG; EPHRIN RECEPTOR A7; PRIMER DNA;

AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SEQUENCE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; BASE SEQUENCE; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTOR, EPHA7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149402919     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23890     Document Type: Article

References (28)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Engl) 2003;116:1391-93.
3. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
4. Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell 1997;90:403-4.
5. Chin-Sang ID, George SE, Ding M, Moseley SL, Lynch AS, Chisholm AD. The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C. elegans. Cell 1999;99: 781-90.
6. Adams RH. Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 2002;13:55-60.
7. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tonillo L. EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 2005;11:6450-8.
8. Vogt T, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, Land-thaler M, McClelland M. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998;4: 791-7.
9. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494-501.
10. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004;10:26-33.
11. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004;95:136-41.
12. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, Ravshanov S, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Konno H, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 2005;96:42-7.
13. Ciossek T, Ullrich A, West E, Rogers JH. Segregation of the receptor EphA7 from its tyrosine kinase-negative isoform on neurons in adult mouse brain. Brain Res Mol Brain Res 1999;74:231-6.
14. Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006;312:642-50.
15. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY. Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 2005;5:86.
16. Sobin LH, Wittekind C. TNM Classification of malignant tumours, 5th edn. New York: Wiley-Liss, 1997;227 p.
17. Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep 2006;16: 429-35.
18. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer 2006;106:79-86.
19. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796-802.
20. Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, Tanaka M, Kanamori M, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005;24:5637-47.
21. Wang J, Li G, Ma H, Bao Y, Wang X, Zhou H, Sheng Z, Sugimura H, Jin J, Zhou X. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 2007;38:1649-56.
22. Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, Morse HC, III, Said J, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 2007;26:4243-52.
23. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33.
24. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY, Naito Y, Yamada K, Sugimura H, Kino I. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994;54:3645-50.
25. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004;50:490-99.
26. Tang XX, Evans AE, Zhao H, Cnaan A, London W, Cohn SL, Brodeur GM, Ikegaki N. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 1999;5:1491-6.
27. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 2004;36:979-83.
28. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de BM, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.